Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: A cohort study from British Columbia, Canada.

Hanley GE, Kwon JS, Finlayson SJ, Huntsman DG, Miller D, McAlpine JN.

Am J Obstet Gynecol. 2018 May 28. pii: S0002-9378(18)30429-0. doi: 10.1016/j.ajog.2018.05.019. [Epub ahead of print]

PMID:
29852159
2.

Changing Clinical Practice: Evaluation of Implementing Recommendations for Opportunistic Salpingectomy in British Columbia and Ontario.

Lander B, Wilcox E, McAlpine JN, Finlayson SJ, Huntsman DG, Miller D, Hanley GE.

Int J Gynecol Cancer. 2018 Jul;28(6):1101-1107. doi: 10.1097/IGC.0000000000001288.

PMID:
29757870
3.

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.

Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP.

Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.

PMID:
29754820
4.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.

Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.

BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.

5.

Authors' Reply.

McAlpine JN, Bosse T.

J Pathol. 2018 Jun;245(2):251. doi: 10.1002/path.5067. Epub 2018 Apr 17. No abstract available.

PMID:
29512825
6.

A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.

Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C, Mitchell G.

BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.

7.

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA.

Am J Surg Pathol. 2018 May;42(5):561-568. doi: 10.1097/PAS.0000000000001020.

PMID:
29505428
8.

Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.

Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A.

Ann Oncol. 2018 May 1;29(5):1180-1188. doi: 10.1093/annonc/mdy058.

PMID:
29432521
9.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.

MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC.

Oncotarget. 2017 Aug 3;8(48):84579-84594. doi: 10.18632/oncotarget.19961. eCollection 2017 Oct 13. Review.

10.

Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.

Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, Kommoss F, Gilks CB, McAlpine JN.

J Pathol Clin Res. 2017 Oct 14;3(4):279-293. doi: 10.1002/cjp2.82. eCollection 2017 Oct.

11.

Foreword.

McAlpine JN.

Clin Obstet Gynecol. 2017 Dec;60(4):685. doi: 10.1097/GRF.0000000000000321. No abstract available.

PMID:
29045295
12.

Risk-reducing Surgery in Women at Low Lifetime Risk of Developing Ovarian Carcinoma: Opportunistic Salpingectomy.

Hanley GE, Rozenberg NMK, McAlpine JN.

Clin Obstet Gynecol. 2017 Dec;60(4):758-770. doi: 10.1097/GRF.0000000000000315. Review.

PMID:
28957952
13.

Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas.

Kumar A, Le N, Gilks CB, Santos JL, Wong F, Swenerton K, Hoskins PJ, McAlpine JN, Tinker AV.

Int J Gynecol Cancer. 2017 Nov;27(9):1819-1825. doi: 10.1097/IGC.0000000000001124.

PMID:
28930809
14.

Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?

Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG.

J Pathol. 2017 Sep;243(1):26-36. doi: 10.1002/path.4934. Epub 2017 Aug 7.

PMID:
28678427
15.

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP.

Nat Genet. 2017 Jun;49(6):856-865. doi: 10.1038/ng.3849. Epub 2017 Apr 24.

PMID:
28436987
16.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N; AOCS study group, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M; EMBRACE Study, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A; GEMO Study Collaborators, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J; HEBON Study, Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K; KConFab Investigators, Kennedy CJ, Khusnutdinova E, Kiemeney LA, Kiiski JI, Kim SW, Kjaer SK, Köbel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larrañaga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubinński J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandiño G, Manoukian S, Massuger LFAG, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Ong KR, Onland-Moret NC; OPAL study group, Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PHM, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permuth JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prieur F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodríguez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, Tan YY, Taylor JA, Tea MK, Teixeira MR, Teo SH, Terry KL, Thompson PJ, Thomsen LCV, Thull DL, Tihomirova L, Tinker AV, Tischkowitz M, Tognazzo S, Toland AE, Tone A, Trabert B, Travis RC, Trichopoulou A, Tung N, Tworoger SS, van Altena AM, Van Den Berg D, van der Hout AH, van der Luijt RB, Van Heetvelde M, Van Nieuwenhuysen E, van Rensburg EJ, Vanderstichele A, Varon-Mateeva R, Vega A, Edwards DV, Vergote I, Vierkant RA, Vijai J, Vratimos A, Walker L, Walsh C, Wand D, Wang-Gohrke S, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, Whittemore AS, Wijnen JT, Wilkens LR, Wolk A, Woo M, Wu X, Wu AH, Yang H, Yannoukakos D, Ziogas A, Zorn KK, Narod SA, Easton DF, Amos CI, Schildkraut JM, Ramus SJ, Ottini L, Goodman MT, Park SK, Kelemen LE, Risch HA, Thomassen M, Offit K, Simard J, Schmutzler RK, Hazelett D, Monteiro AN, Couch FJ, Berchuck A, Chenevix-Trench G, Goode EL, Sellers TA, Gayther SA, Antoniou AC, Pharoah PDP.

Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27.

17.

HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course.

McAlpine JN, Kim SY, Akbari A, Eshragh S, Reuschenbach M, von Knebel Doeberitz M, Prigge ES, Jordan S, Singh N, Miller DM, Gilks CB.

Int J Gynecol Pathol. 2017 Nov;36(6):507-516. doi: 10.1097/PGP.0000000000000375.

PMID:
28319571
18.

Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study.

McAlpine JN, Leung SCY, Cheng A, Miller D, Talhouk A, Gilks CB, Karnezis AN.

Histopathology. 2017 Aug;71(2):238-246. doi: 10.1111/his.13205. Epub 2017 May 23.

PMID:
28257152
19.

Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.

Hoang LN, Kinloch MA, Leo JM, Grondin K, Lee CH, Ewanowich C, Köbel M, Cheng A, Talhouk A, McConechy M, Huntsman DG, McAlpine JN, Soslow RA, Gilks CB.

Am J Surg Pathol. 2017 Feb;41(2):245-252. doi: 10.1097/PAS.0000000000000764.

PMID:
28079598
20.

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN.

Cancer. 2017 Mar 1;123(5):802-813. doi: 10.1002/cncr.30496. Epub 2017 Jan 6.

21.

Fluorescence confocal endomicroscopy of the cervix: pilot study on the potential and limitations for clinical implementation.

Schlosser C, Bodenschatz N, Lam S, Lee M, McAlpine JN, Miller DM, Van Niekerk DJ, Follen M, Guillaud M, MacAulay CE, Lane PM.

J Biomed Opt. 2016 Dec 1;21(12):126011. doi: 10.1117/1.JBO.21.12.126011.

PMID:
27999860
22.

New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.

Talhouk A, McAlpine JN.

Gynecol Oncol Res Pract. 2016 Dec 13;3:14. doi: 10.1186/s40661-016-0035-4. eCollection 2016. Review.

23.

The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States.

Hanley GE, McAlpine JN, Pearce CL, Miller D.

Am J Obstet Gynecol. 2017 Mar;216(3):270.e1-270.e9. doi: 10.1016/j.ajog.2016.10.035. Epub 2016 Nov 1.

PMID:
27810554
24.

FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor.

Färkkilä A, McConechy MK, Yang W, Talhouk A, Ng Y, Lum A, Morin RD, Bushell K, Riska A, McAlpine JN, Gilks CB, Unkila-Kallio L, Anttonen M, Huntsman DG.

J Mol Diagn. 2017 Jan;19(1):126-136. doi: 10.1016/j.jmoldx.2016.08.005. Epub 2016 Nov 1.

PMID:
27810330
25.

In-depth molecular profiling of the biphasic components of uterine carcinosarcomas.

McConechy MK, Hoang LN, Chui MH, Senz J, Yang W, Rozenberg N, Mackenzie R, McAlpine JN, Huntsman DG, Clarke BA, Gilks CB, Lee CH.

J Pathol Clin Res. 2015 Apr 9;1(3):173-85. doi: 10.1002/cjp2.18. eCollection 2015 Jul.

26.

Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.

Talhouk A, Hoang LN, McConechy MK, Nakonechny Q, Leo J, Cheng A, Leung S, Yang W, Lum A, Köbel M, Lee CH, Soslow RA, Huntsman DG, Gilks CB, McAlpine JN.

Gynecol Oncol. 2016 Oct;143(1):46-53. doi: 10.1016/j.ygyno.2016.07.090. Epub 2016 Jul 14.

27.

Endometrial cancer: Not your grandmother's cancer.

McAlpine JN, Temkin SM, Mackay HJ.

Cancer. 2016 Sep 15;122(18):2787-98. doi: 10.1002/cncr.30094. Epub 2016 Jun 16. Review.

28.

La salpingectomie opportuniste : Nous choisissons d'agir, pas d'attendre.

McAlpine JN, Tone AA, Hanley GE.

J Obstet Gynaecol Can. 2016 May;38(5):428-31. doi: 10.1016/j.jogc.2016.04.090. No abstract available.

PMID:
27261216
29.

Opportunistic Salpingectomy: We Chose to Act, Not Wait.

McAlpine JN, Tone AA, Hanley GE.

J Obstet Gynaecol Can. 2016 May;38(5):425-7. doi: 10.1016/j.jogc.2016.04.084. Epub 2016 May 6. No abstract available.

PMID:
27261215
30.

Diffuse optical microscopy for quantification of depth-dependent epithelial backscattering in the cervix.

Bodenschatz N, Lam S, Carraro A, Korbelik J, Miller DM, McAlpine JN, Lee M, Kienle A, MacAulay C.

J Biomed Opt. 2016 Jun 1;21(6):66001. doi: 10.1117/1.JBO.21.6.066001. No abstract available.

PMID:
27251077
31.

Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer.

Fujiwara K, McAlpine JN, Lheureux S, Matsumura N, Oza AM.

Am Soc Clin Oncol Educ Book. 2016;35:e247-57. doi: 10.14694/EDBK_158675. Review.

32.

Clonal genotype and population structure inference from single-cell tumor sequencing.

Roth A, McPherson A, Laks E, Biele J, Yap D, Wan A, Smith MA, Nielsen CB, McAlpine JN, Aparicio S, Bouchard-Côté A, Shah SP.

Nat Methods. 2016 Jul;13(7):573-6. doi: 10.1038/nmeth.3867. Epub 2016 May 16.

PMID:
27183439
33.

Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.

McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice LM, Khattra J, Smith MA, Nielsen CB, Mullaly SC, Kalloger S, Karnezis A, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall AJ, Marra MA, Bouchard-Côté A, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP.

Nat Genet. 2016 Jul;48(7):758-67. doi: 10.1038/ng.3573. Epub 2016 May 16.

PMID:
27182968
34.

Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.

Köbel M, Atenafu EG, Rambau PF, Ferguson SE, Nelson GS, Ho TC, Panzarella T, McAlpine JN, Gilks CB, Clarke BA, Bernardini MQ.

Gynecol Oncol. 2016 Jun;141(3):559-563. doi: 10.1016/j.ygyno.2016.04.008. Epub 2016 Apr 16.

PMID:
27072807
35.

Subpubic Cartilaginous Cyst: A Rare Sub-Clitoral Mass.

Healy CF, Pang E, Bakhsh S, White L, McAlpine JN, Yee WC, Harris AC.

J Obstet Gynaecol Can. 2016 Feb;38(2):102-3. doi: 10.1016/j.jogc.2015.12.005. Epub 2016 Feb 26. English, French. No abstract available.

PMID:
27032732
36.

Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC).

Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson SE, Köbel M, Samouëlian V, Wesa M, Cameron A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu EG, McAlpine JN.

Gynecol Oncol. 2016 Apr;141(1):148-54. doi: 10.1016/j.ygyno.2016.02.002. Epub 2016 Feb 5.

PMID:
26854651
37.

Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.

McConechy MK, Talhouk A, Leung S, Chiu D, Yang W, Senz J, Reha-Krantz LJ, Lee CH, Huntsman DG, Gilks CB, McAlpine JN.

Clin Cancer Res. 2016 Jun 15;22(12):2865-73. doi: 10.1158/1078-0432.CCR-15-2233. Epub 2016 Jan 13.

38.

p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases.

Cheng AS, Karnezis AN, Jordan S, Singh N, McAlpine JN, Gilks CB.

Int J Gynecol Pathol. 2016 Jul;35(4):385-93. doi: 10.1097/PGP.0000000000000263.

PMID:
26630231
39.

Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.

Bakhsh S, Kinloch M, Hoang LN, Soslow RA, Köbel M, Lee CH, McAlpine JN, McConechy MK, Gilks CB.

Histopathology. 2016 May;68(6):916-24. doi: 10.1111/his.12878. Epub 2015 Dec 17.

40.

Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers.

Altman AD, Ferguson SE, Atenafu EG, Köbel M, McAlpine JN, Panzarella T, Lau S, Gien LT, Gilks B, Clarke B, Cameron A, Nelson G, Han G, Samouëlian V, Ho TC, Louie K, Bernardini MQ.

Gynecol Oncol. 2015 Nov;139(2):268-74. doi: 10.1016/j.ygyno.2015.09.001. Epub 2015 Sep 6.

PMID:
26352641
41.

A clinically applicable molecular-based classification for endometrial cancers.

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN.

Br J Cancer. 2015 Jul 14;113(2):299-310. doi: 10.1038/bjc.2015.190. Epub 2015 Jun 30.

42.

Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.

Hoang LN, McConechy MK, Köbel M, Anglesio M, Senz J, Maassen M, Kommoss S, Meng B, Postovit L, Kelemen LE, Staebler A, Brucker S, Krämer B, McAlpine JN, Gilks CB, Huntsman DG, Lee CH.

Int J Gynecol Cancer. 2015 Sep;25(7):1187-93. doi: 10.1097/IGC.0000000000000492.

PMID:
26166557
43.

Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling: A Prospective Study Comparing Cytology, Frozen Section, and Core Biopsies to Full Pathologic Examination.

Hoang LN, Zachara S, Soma A, Köbel M, Lee CH, McAlpine JN, Huntsman D, Thomson T, van Niekerk D, Singh N, Gilks CB.

Int J Gynecol Pathol. 2015 Nov;34(6):517-27. doi: 10.1097/PGP.0000000000000199.

PMID:
26107565
44.

The more tumors change, the more they stay tame: do T cells keep POLE ultramutated endometrial carcinomas in check?

Nelson BH, McAlpine JN.

Gynecol Oncol. 2015 Jul;138(1):1-2. doi: 10.1016/j.ygyno.2015.06.004. No abstract available.

PMID:
26072691
45.

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.

BMC Cancer. 2015 May 19;15:415. doi: 10.1186/s12885-015-1421-8.

46.

Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors.

Burleigh A, Talhouk A, Gilks CB, McAlpine JN.

Gynecol Oncol. 2015 Jul;138(1):141-6. doi: 10.1016/j.ygyno.2015.02.028. Epub 2015 Apr 12.

PMID:
25870916
47.

Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.

McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN.

Gynecol Oncol. 2015 May;137(2):306-10. doi: 10.1016/j.ygyno.2015.01.541. Epub 2015 Jan 28.

PMID:
25636458
48.

Population distribution of lifetime risk of ovarian cancer in the United States.

Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, Lee AW, Menon U, Fasching PA, McAlpine JN, Doherty JA, Modugno F, Schildkraut JM, Rossing MA, Huntsman DG, Wu AH, Berchuck A, Pike MC, Pharoah PDP.

Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):671-676. doi: 10.1158/1055-9965.EPI-14-1128. Epub 2015 Jan 26.

49.

Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy.

Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, Gilks CB, Huntsman DG.

Obstet Gynecol. 2015 Feb;125(2):338-45. doi: 10.1097/AOG.0000000000000630.

PMID:
25568991
50.

Opportunistic salpingectomy for ovarian cancer prevention.

Hanley GE, McAlpine JN, Kwon JS, Mitchell G.

Gynecol Oncol Res Pract. 2015 Sep 17;2:5. doi: 10.1186/s40661-015-0014-1. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center